MARKET

PRRUF

PRRUF

Immutep Ltd
OTCPK
0.050
NaN%
Opening 09:30 08/19 EDT
OPEN
--
PREV CLOSE
0.050
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.334
52 WEEK LOW
0.040
MARKET CAP
73.69M
P/E (TTM)
-1.3089
1D
5D
1M
3M
1Y
5Y
1D
Immutep balances TACTI-004 setback with upbeat efti and IMP761 data
TipRanks · 07/29 22:55
Immutep’s Sarcoma Quality-of-Life Data Accepted for ESMO 2026
TipRanks · 07/23 23:18
Immutep granted new patent for eftilagimod alfa combination
TipRanks · 07/14 12:15
Immutep Wins Fourth U.S. Patent for Key Cancer Immunotherapy Combination
TipRanks · 07/14 02:22
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Barchart · 07/13 07:00
Immutep Posts Strong NSCLC Survival Data as It Probes Phase III Setback
TipRanks · 07/12 23:48
JPMorgan Group Ceases to Be Substantial Holder in Immutep
TipRanks · 06/30 23:03
Immutep upgraded to Buy from Hold at Maxim
TipRanks · 06/17 12:06
More
About PRRUF
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd stock information, including OTCPK: PRRUF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRRUF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRRUF stock methods without spending real money on the virtual paper trading platform.